Psychopharmacology of substance misuse and comorbid psychiatric disorders

Acta Neuropsychiatrica

Volumn 16, Issue 1, 2004, Pages 19-25

  Abou Saleh, Mohammed T ^a  

^a City Mental Health NHS Trust   (United Kingdom)

Author keywords

Comorbid; Psychiatric; Psychopharmacology substance misuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; ANANDAMIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID; CANNABIS; CLOZAPINE; DOPAMINE; FLUOXETINE; IMIPRAMINE; LYSERGIDE; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; OXAZEPAM; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; BEHAVIOR THERAPY; BIPOLAR DISORDER; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPHORIA; HUMAN; LIMBIC CORTEX; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; NEGATIVE SYNDROME; PATIENT CARE; PSYCHOPHARMACOLOGY; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; REWARD; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF MEDICATION; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SOCIAL PHOBIA; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE;

EID: 1542376681     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2004.0061.x     Document Type: Review

References (54)

1. KESSLER RC, MCCONGALE KA, ZHAO S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51: 8-19.
2. FARRELL M, HOWES S, BEBBINGTON P et al. Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey. Br J Psychiatry 2001;179:432-437.
3. REGIER DA, MYERS JK, KRAMER M et al. The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984;41:934-941.
4. LAINE TP, AHONEN A, RASANEN P, TIIHONEN J. Dopamine transporter availability and depressive symptoms alcohol withdrawal. Psychiatry Res 1999;90:153-157.
5. SIRIS SG. Pharmacological treatment of substance-abusing schizophrenic patients. Shizophr Bull 1990;16: 111-122.
6. MCEVOY J, FREUDENREICH O, MCGEE M, VANDERZWAAG C, LEVIN E, ROSE J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995;37:550-552.
7. DOSE M, TEMPEL HD. Abuse potential of anticholinergics. Pharmacopsychiatry 2000;33 (Suppl. 1):43-46.
8. CHAMBERS RA, KRYSTAL JH, SELF DW. A neurobiological basis for substance abuse comordibity in schizophrenia. Biol Psychiatry 2001;50:71-83.
9. WEISS R, NAJAVITS L. Overview of treatment modalities for dual diagnosis patients: Pharmacotherapy, psychotherapy, and 12-step programmes. In: KRANZLER H, ROUNSAVILLE B, eds. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York, NY: Marcel Dekker Inc., 1998:87.
10. SAXON AJ, CALSYN DA. Effects of psychiatric care for dual diagnosis patients treated in a drug dependence clinic. Am J Drug Alcohol Abuse 1995;21:303-313.
11. MCGRATH PJ, NUNES EV, STEWART JW, GOLDMAN D, AGOSTI V, OCEPEK-WELIKSON K, QUITKIN FM. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 1996;53:232-240.
12. NUNES EV, QUITKIN FM, BRADY R, STEWART JW. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 1991;148:667-669.
13. CORNELIUS JR, SALLOUM IM, CORNELIUS MD et al. Fluoxetine in depressed alcoholics. A double blind placebo-controlled trial. Arch Gen Psychiatry 1997;54: 700-705.
14. KHANTZIAN EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4:231-244.
15. NOORDSY DL, DRAKE RE, TEAGUE GB et al. Subjective experiences related to alcohol use among schizophrenics. J Nerv Ment Dis 1991;179:410-414.
16. ALBANESE MJ, KHANTZIAN EJ, MURPHY SL, GREEN AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994;151:780.
17. MUESER KT, YARNOLD PR, LEVINSON DF, SINGH H, BELLACK AS, KEE K, MORRISON RL, YADALAM KG. Prevalence of substance abuse in schizophrenia: demographical clinical correlates. Schizophr Bull, 1990;16: 31-56.
18. FADDA F, MOSCA E, COLOMBO G, GESSA GL. Effect of spontaneous ingestion of ethanol on brain dopamine metabolism. Life Sci, 1989;44:281-287.
19. NISSEL M, NOMIKOS GG, SVENSSON TH. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharm Toxicol, 1995;76:157-162.
20. GREEN AL, TSUANG MT, SCHILDKRAUT JJ. Catecholamines, their metabolites, and response to typical and atypical neuroleptics: Toward an understanding of the mechanisms of action of neuroleptic drugs. In: FRIEDHOFF, AJ, AMIN, F, eds. Plasma Homovanillic Acid in Schizophrenia. APA Press, Inc.: 1997:61-77.
21. SCHNEIDER U, LEWEKE FM, MUELLER-VAHL KR, EMRICH HM. Cannabiniod/ anandamide system and schizophrenia: is there evidence for association? Pharmacopsychiatry 1998;2 (Suppl. 31):110-113.
22. LEWEKE FM, FUIFFRIDA A, WURSTER U, EMRICH HM, PIOMELLI D. Elevated endogenous cannabiniods in schizophrenia. Neuroreport, 1999 June 3;10:1665-1669.
23. PARROTT AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001;16:557-577.
24. LANDABASO MA, IRAURGI I, JIMENEZ-LERMA JM, CALLE R, SANZ J, GUTIERREZ-FRAILE M. Ecstasy-induced psychotic disorder: six month follow-up study. Eur Addict Res 2002;8:133-140.
25. ZIMMET SV, STROUS RD, BURGESS ES, KOHNSTAMM S, GREEN AI. Effects of clozapine on substance use in patients with schizophrenic and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000;20: 94-98.
26. IMPERATO A, Di CHIARA G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharm Exp Ther 1986;239:219-228.
27. PROCYSHYN RM, IHSAN N, THOMPSON D. A comparison of smoking behaviours between patients treated with risperidone. Int Clin Psychopharmacol 2001;16: 291-294.
28. DRAKE RE, ZIE H, MCHUGO CJ, GREEN AI. The effects of clozapine on alcohol and drug use disorders and patients with schizophrenia. Schizophr Bull 2000;26: 441-449.
29. HASIN D, NUNES E. Comorbidity of alcohol, drug, and psychiatric disorders. In: KRANZLER H, ROUNSAVILLE B, eds. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York, NY: Marcel Dekker Inc., 1998:1-30.
30. LITTRELL KH, PETTY RG, HILLIGOSS NM, PEABODY CD, JOHNSON CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21:217-221.
31. CASAS M, GUTIERREZ M, GILBERT J, BOBES J, RONCERO C, OCTAVIO I. Risperidone in the treatment of psychotic patients with opiate abuse and dependence. Actas Esp Psiquiatr 2001;29:380-385.
32. GREEN AI, BURGESS ES, DAWSON R, ZIMMET SV, STROUS RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 2003;60:81-85.
33. HASIN D, LIU X, NUNES E, MCCLOUD S, SAMET S, ENDICOTT J. Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002;59:375-380.
34. ABOU-SALEH MT, MERRY J, COPPEN A. Dexamethasone suppression test in alcoholism. Acta Psychiatr Scand 1984;69:112-116.
35. MUESER KT, DRAKE RE, WALLACH MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998;23: 717-734.
36. POST RM, SILBERSTEIN SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology 1994;44 (Suppl. 7):S37-S47.
37. VOLKOW ND, WANG GJ, FOWLER JS et al. Relationship between blockade of dopamine transporters by methylphenidate and the increases in extracellular dopamine therapeutic implications. Synapse 2002;43:181-187.
38. ANAND A, VERHOEFF P, SENECA N, ZOGHBI SS, SEIBYL JP, CHARNEY DS. Brain SPECT imagine of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000;157:1108-1114.
39. MALCOLM R, BALLENGER JC, STURGIS ET, ANTON R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989;146:617-621.
40. MACRITCHIE KA, GEDDES JR, SCOTT J, HASLAM DR, GOODWIN GM. Valporic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001;3:CD003196.
41. BRADY KT, SONNE SC, ANTON R, BALLENGER JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995;56:118-121.
42. COOKSON J. Use of antipsychotic drugs and lithium in mania. Br J Psychiatry Suppl, 2001;41:s148-s156.
43. HERSH D, MODESTO-LOWE V. Drug abuse and mood disorders. In: KRANZLER H, ROUNSAVILLE B, eds. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York, NY: Marcel Dekker Inc., 1998:177-201.
44. BALLENGER JC, GOODWIN FK, MAJOR LF, BROWN GL. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 1979;36:224-227.
45. GOLD MS, DACKIS CA. New insights and treatments: opiate withdrawal and cocaine addiction. Clin Ther 1984;7:6-21.
46. MASON BJ, KOCSIS JH, RITVO EC, CUTLER RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275:803-804.
47. MASON BJ. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res 1996;20 (Suppl. 7):10A-16A.
48. NUNES EV, McGRATH PJ, QUITKIN FM et al. Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry 1993;150:963-965.
49. KRANZLER HR, BURLESON JA, KORNER P et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995;152:391-397.
50. SCHMITZ JM, AVERILL P, STOTTS AL, MOELLER FG, RHOADES HM, GRABOWSKI J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001;63:207-214.
51. LANDABASO MA, IRAURGI I, JIMENEZ-LERMA JM, SANZ J et al. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction 1998;93:739-744.
52. GAWIN FH, KLEBER HD, BYCK R et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989;46:117-121.
53. ZIEDONIS DM, KOSTEN TR. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs Dec 1991;23:417-425.
54. CARROL KM, NICH C, ROUNSAVILLE BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacology. J Nerv Ment Dis 1995;183:251-259.